Literature DB >> 21726995

Non-immunoglobulin based protein scaffolds.

John Löfblom1, Fredrik Y Frejd, Stefan Ståhl.   

Abstract

Non-immunoglobulin based protein scaffolds have been reported as promising alternatives to traditional monoclonal antibodies for over a decade and are often mentioned as part of the next-generation immunotherapeutics. Today, this class of biologics is beginning to demonstrate its potential for therapeutic applications and several are currently in preclinical or clinical development. A common denominator for most of these new scaffolds is the attractive properties that differentiate them from monoclonal antibodies including small size, cysteine-free sequence, flexible pharmacokinetic properties, and ease of generating multispecific molecules. In addition to therapeutic applications, substantial evidence point to superior performance of several of these scaffolds in molecular imaging compared to full-length antibodies. Here we review the most recent progress using alternative protein scaffolds for therapy and medical imaging.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21726995     DOI: 10.1016/j.copbio.2011.06.002

Source DB:  PubMed          Journal:  Curr Opin Biotechnol        ISSN: 0958-1669            Impact factor:   9.740


  45 in total

1.  Optimization of designed armadillo repeat proteins by molecular dynamics simulations and NMR spectroscopy.

Authors:  Pietro Alfarano; Gautham Varadamsetty; Christina Ewald; Fabio Parmeggiani; Riccardo Pellarin; Oliver Zerbe; Andreas Plückthun; Amedeo Caflisch
Journal:  Protein Sci       Date:  2012-09       Impact factor: 6.725

2.  Surface display of a single-domain antibody library on Gram-positive bacteria.

Authors:  Filippa Fleetwood; Nick Devoogdt; Mireille Pellis; Ulrich Wernery; Serge Muyldermans; Stefan Ståhl; John Löfblom
Journal:  Cell Mol Life Sci       Date:  2012-10-13       Impact factor: 9.261

Review 3.  Distinct antibody species: structural differences creating therapeutic opportunities.

Authors:  Serge Muyldermans; Vaughn V Smider
Journal:  Curr Opin Immunol       Date:  2016-02-27       Impact factor: 7.486

4.  Consensus design of a NOD receptor leucine rich repeat domain with binding affinity for a muramyl dipeptide, a bacterial cell wall fragment.

Authors:  Rachael Parker; Ana Mercedes-Camacho; Tijana Z Grove
Journal:  Protein Sci       Date:  2014-04-17       Impact factor: 6.725

Review 5.  Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment.

Authors:  James R Kintzing; Maria V Filsinger Interrante; Jennifer R Cochran
Journal:  Trends Pharmacol Sci       Date:  2016-11-09       Impact factor: 14.819

Review 6.  Beyond Antibodies as Binding Partners: The Role of Antibody Mimetics in Bioanalysis.

Authors:  Xiaowen Yu; Yu-Ping Yang; Emre Dikici; Sapna K Deo; Sylvia Daunert
Journal:  Annu Rev Anal Chem (Palo Alto Calif)       Date:  2017-03-24       Impact factor: 10.745

7.  Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling.

Authors:  Ykelien L Boersma; Ginger Chao; Daniel Steiner; K Dane Wittrup; Andreas Plückthun
Journal:  J Biol Chem       Date:  2011-10-06       Impact factor: 5.157

8.  Fibronectin type III domains engineered to bind CD40L: cloning, expression, purification, crystallization and preliminary X-ray diffraction analysis of two complexes.

Authors:  Vaheh Oganesyan; Andrew Ferguson; Luba Grinberg; Lin Wang; Sandrina Phipps; Benoy Chacko; Stacey Drabic; Thomas Thisted; Manuel Baca
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2013-08-21

9.  A new prodrug form of Affibody molecules (pro-Affibody) is selectively activated by cancer-associated proteases.

Authors:  Lisa Sandersjöö; Andreas Jonsson; John Löfblom
Journal:  Cell Mol Life Sci       Date:  2014-10-07       Impact factor: 9.261

10.  Development and characterization of small bispecific albumin-binding domains with high affinity for ErbB3.

Authors:  Johan Nilvebrant; Mikael Astrand; John Löfblom; Sophia Hober
Journal:  Cell Mol Life Sci       Date:  2013-06-02       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.